Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 8/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18283000 | 0.79 | TYMS (0.40) | TYMSMAPK1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL22423037 | 0.77 | MAPK1 (0.38) | TYMSMAPK1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL20156665 | 0.75 | HCAR2 (0.43) | TYMSMAPK1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL22423036 | 0.74 | MAPK1 (0.36) | TYMSMAPK1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL7851196 | 0.70 | TYMS (0.48) | TYMSMAPK1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL2902002 | 0.65 | TSHR (0.43) | PARP1ALDH1A1CYP1A2TNKS2 | |
| SCHEMBL12894711 | 0.65 | DYRK1A (0.31) | — | |
| SCHEMBL23986364 | 0.65 | AURKA (0.31) | — | |
| SCHEMBL14337027 | 0.64 | PARP1 (0.50) | TYMSMAPK1PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL9996283 | 0.64 | ALDH1A1 (0.54) | TYMSMAPK1PARP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562828-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250136604-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| CN-110337437-B | Substituted pyrazolopyrimidinones as PDE2 inhibitors | 达特神经科学有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-11-04 | — | — | US | disclosed |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | DART NEUROSCIENCE, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| EP-3302484-B1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3302484-B1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3562828-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Dart NeuroScience LLC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-12-25 | — | — | US | disclosed |
| WO-2018125810-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2018-07-05 | — | — | WO | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3302484-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196071-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016191935-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196071-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160762-B2 | 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE4D | TYMS 2188/4885MAPK1 1256/4885PARP1 1458/4885 |
| US-20180134712-A1 | 6-ALKYL DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | TYMS 2188/4885MAPK1 1256/4885PARP1 1458/4885 |
| US-11999738-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE3B | TYMS 451/4885MAPK1 1767/4885PARP1 220/4885 |
| US-20210340145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3B | TYMS 451/4885MAPK1 1767/4885PARP1 220/4885 |
| US-10981916-B2 | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, TDP2 | TYMS 352/4885MAPK1 1769/4885PARP1 309/4885 |
| US-20250136604-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE3B | TYMS 451/4885MAPK1 1767/4885PARP1 220/4885 |
| US-20200148685-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | TYMS 352/4885MAPK1 1769/4885PARP1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.